Unfortunately, there are no data to support the use of ezetimibe
in patients with secondary hypercholesterolemia.
In an unexpected finding, pathologist and co-author Dolores Di Vizio, MD, PhD, observed that finasteride caused atrophy of the hamster prostate while ezetimibe
Many clinical studies show that the co-administration of statins together with Ezetimibe
is a more successful treatment than a single statin therapy (Shepherd 2003; Shepherd 2001; Davidson et al.
The results of outcome studies looking at hard clinical endpoints with ezetimibe
are eagerly awaited.
However, two weeks before presentation, her simvastatin (at a dosage of 20 mg) was changed to a combined formulation of simvastatin and ezetimibe
in a dosage of 20 mg and 10 mg, respectively.
(risk factor C) selectively inhibits the intestinal absorption of cholesterol and related phytosterols.
(Zetia), a cholesterol absorption blocker acting in the small intestine, also was introduced in 2003.
com/research/z2rjsb/investigation) has announced the addition of the "Investigation Report on China's Ezetimibe
Market, 2010-2019" report to their offering.
For some time the FDA has, on occasion, approved drugs that can lower cholesterol with limited outcome data as it did with ezetimibe
Table 1: KDIGO 2013 recommendations on statin therapy in adult patients with CKD Patient Group Recommendation Level of recommendation * [greater than or equal to] Treatment with a 1A 50 years with eGFR [less statin or statin/ than or equal to] 60 ml/ ezetimibe
Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe
and atorvastatin tablets, an investigational combination medicine.
Tenders are invited for Supply of Atorvastatin 10 Mg Plus Ezetimibe
SAN DIEGO -- The presentation of the landmark IMPROVE-IT study at last November's American Heart Association scientific sessions told only half the story of the clinical impact of lipid-lowering with the combination of ezetimibe
and simvastatin as opposed to simvastatin alone.
However, the addition of ezetimibe
may be required if statin monotherapy fails to lower LDL-C to target levels, the investigators report in the Journal of the American College of Cardiology for December 16/23.
The study, called ENHANCE (Effect of Combination Ezetimibe
and High-Dose Simvastatin versus Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia), was designed to determine if an anticipated additional reduction in LDL-cholesterol (LDLc) of 18% when ezetimibe
10 mg was added to 80 mg of simvastatin (Vytorin 10/80 mg) versus 80 mg simvastatin alone would result in either less progression or more regression of carotid atherosclerosis as measured by intima-media thickening (cIMT).